secwatch / observer
8-K filed August 10, 2022, 7:59 PM ET ticker LFCR CIK 0001005286
other material confidence high sentiment neutral materiality 0.85

Landec reports Q4 net loss $35.9M, announces CEO change and rebranding

LIFECORE BIOMEDICAL, INC. DE

item 2.02item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Albert Bolles

Chief Executive Officer
LFCR · LIFECORE BIOMEDICAL, INC. DE
Effective
2022-08-10
Successor
James G. Hall
Filed
August 10, 2022, 7:59 PM ET
In accordance with the Separation Agreement, Dr. Bolles resigned as the Company’s Chief Executive Officer and as a director of the Board of Directors of the Company (the “Board), effective immediately, to transition to serve as President of Curation Foods, Inc., a wholly owned subsidiary of the Company.
Departed

Deborah Carosella

Director
LFCR · LIFECORE BIOMEDICAL, INC. DE
Filed
August 10, 2022, 7:59 PM ET
Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.
Appointed

James G. Hall

Chief Executive Officer
LFCR · LIFECORE BIOMEDICAL, INC. DE
Effective
2022-08-10
Filed
August 10, 2022, 7:59 PM ET
On August 10, 2022, the Board appointed James G. Hall as the Company’s Chief Executive Officer and as a director of the Board, succeeding Dr. Albert Bolles, to serve in such capacities until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Departed

Andrew Powell

Director
LFCR · LIFECORE BIOMEDICAL, INC. DE
Filed
August 10, 2022, 7:59 PM ET
Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)
Departed

Tonia Pankopf

Director
LFCR · LIFECORE BIOMEDICAL, INC. DE
Filed
August 10, 2022, 7:59 PM ET
Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.
Departed

Catherine A. Sohn

Director
LFCR · LIFECORE BIOMEDICAL, INC. DE
Filed
August 10, 2022, 7:59 PM ET
Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Albert Bolles resigned as Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.

Action
resigned
Role
Chief Executive Officer
Exact text from the filing
In accordance with the Separation Agreement, Dr. Bolles resigned as the Company’s Chief Executive Officer and as a director of the Board of Directors of the Company (the “Board), effective immediately, to transition to serve as President of Curation Foods, Inc., a wholly owned subsidiary of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Deborah Carosella departed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action
resign
Role
Director
Exact text from the filing
Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

James G. Hall was appointed as Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
On August 10, 2022, the Board appointed James G. Hall as the Company’s Chief Executive Officer and as a director of the Board, succeeding Dr. Albert Bolles, to serve in such capacities until his successor is duly elected and qualified or until his earlier death, resignation or removal.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Andrew Powell departed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action
not stand for re-election
Role
Director
Exact text from the filing
Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Tonia Pankopf departed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action
resign
Role
Director
Exact text from the filing
Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Catherine A. Sohn departed as Director at LIFECORE BIOMEDICAL, INC. DE.

Action
not stand for re-election
Role
Director
Exact text from the filing
Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)
View on SEC.gov

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR
accession 0001005286-22-000029
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.